Body’s Own Gene Editing System Generates Leukemia Stem Cells

Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers —

Cancer stem cells are like zombies — even after a tumor is destroyed, they can keep coming back. These cells have an unlimited capacity to regenerate themselves, making more cancer stem cells and more tumors. Researchers at University of California San Diego School of Medicine have now unraveled how pre-leukemic white blood cell precursors become leukemia stem cells. The study, published June 9 in Cell Stem Cell, used human cells to define the RNA editing enzyme ADAR1’s role in leukemia, and find a way to stop it. … Read the Full Story from the UC San Diego Newsroom


Catriona H. M. Jamieson, MD, PhD

Catriona H. M. Jamieson, MD, PhD

The senior author of the study report is Catriona Jamieson, MD, PhD, Associate Professor of Medicine and Chief of the Division of Regenerative Medicine.

Dr. Jamieson is Deputy Director of the Sanford Stem Cell Clinical Center at UC San Diego Health, Director of the CIRM Alpha Stem Cell Clinic at UC San Diego School of Medicine and Director of Stem Cell Research at UC San Diego Moores Cancer Center.

UC San Diego Division of Regenerative Medicine coauthors include Sheldon Morris, MD, MPH, Data Management Lead for the UC San Diego CIRM Alpha Stem Cell Clinic; co-first authors Maria Anna Zipeto and Angela C. Court, Anil Sadarangani, Nathaniel P. Delos Santos, Larisa Balaian, Gabriel Pineda, Cayla N. Mason, Ifat Geron, Daniel J. Goff, Russell Wall, Leslie A. Crews and Qingfei Jiang.

Read the study report (UC San Diego only)

Visit the Jamieson Lab Website

Dr. Catriona Jamieson Receives Excellence in Stewardship Award

Catriona H. M. Jamieson, MD, PhD

Catriona Jamieson, MD, PhD

Dr. Catriona Jamieson is one of three UC San Diego faculty and staff members to receive an Excellence in Stewardship Award this year.

In his announcement to the campus community on April 21, Chancellor Pradeep K. Khosla said, “The UC San Diego community defines exemplary stewardship as taking every measure to ensure that our supporters – donors, volunteers, corporate partners and foundations – understand the full impact and importance of their involvement with UC San Diego.

“Excellent stewardship goes beyond saying ‘thank you’ and instills pride and further engagement by fully communicating to supporters all that their engagement has made possible.”

Catriona Jamieson, MD, PhD, is Associate Professor of Medicine, Chief of the Division of Regenerative Medicine, Deputy Director of the Sanford Stem Cell Clinical Center, Co-Leader of the Hematologic Malignancies Program and Director of the Moores Cancer Center Stem Cell Research Program.

She and the other honorees will be recognized at the annual UC San Diego Foundation Dinner on June 2, 2016. The award is presented by the Trustees of the UC San Diego Foundation Board.

More information is available on the UC San Diego Excellence in Stewardship website.

New Drug for Blood Cancers Now in Five Phase II Clinical Trials

Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology.

The drug is a small molecule inhibitor that suppresses the activity of a signaling pathway believed to contribute to a variety of blood cancers’ eventual resistance to standard chemotherapy treatments. … Read the Full Story from the UC San Diego News Center


Catriona Jamieson, MD, PhD, Catriona H. M. Jamieson, MD, PhD is the senior author of the article reporting the multicenter study. Dr. Jamieson is an associate professor of medicine and chief of the Division of Regenerative Medicine in the School of Medicine.

Read summary of article in The Lancet Haematology

Division of Regenerative Medicine Holds First Research Symposium

Catriona H. M. Jamieson, MD, PhD

Dr. Catriona Jamieson

On Friday, January 30, the Division of Regenerative Medicine presented its inaugural symposium on novel research and technologies in regenerative medicine.

The meeting featured scientific presentations by world-renowned academic investigators and industry leaders as well as a discussion panel including keynote speakers Dr. Hans Clevers, Dr. Derrick Rossi, Dr. Carl June and Dr. Wolfgang Dillmann.

Division Chief Catriona Jamieson, MD, PhD, presented the mission and milestones of the new Division of Regenerative Medicine after introductions from UC San Diego Chancellor Pradeep Khosla; Vice Chancellor Health Sciences and Dean of UC San Diego School of Medicine Dr. David Brenner; and Chief Executive Officer of UC San Diego Health System and Associate Vice Chancellor of UC San Diego Health Sciences Paul Viviano.

UC San Diego Moores Cancer Center

UC San Diego Moores Cancer Center

Catriona Jamieson, MD, PhD, is associate professor in the Division of Hematology-Oncology, deputy director of the Sanford Stem Cell Clinical Center, chief of the Division of Regenerative Medicine and director of stem cell research at the Moores Cancer Center.

UC San Diego Named Stem Cell “Alpha Clinic”

Designation will help speed development of emerging drugs and therapies —

In a push to further speed clinical development of emerging stem cell therapies, Sanford Stem Cell Clinical Center at UC San Diego Health System was named today one of three new “alpha clinics” by the California Institute for Regenerative Medicine (CIRM), the state’s stem cell agency.

The announcement, made at a public meeting in Los Angeles of the CIRM Governing Board, includes an award of $8 million for each of three sites. The other alpha grant recipients are the City of Hope hospital near Los Angeles and University of California, Los Angeles.

“A UC San Diego alpha clinic will provide vital infrastructure for establishing a comprehensive regenerative medicine clinical hub that can support the unusual complexity of first-in-human stem cell-related clinical trials,” said Catriona Jamieson, MD, PhD, associate professor of medicine at UC San Diego School of Medicine, deputy director of the Sanford Stem Cell Clinical Center, director of the UC San Diego Moores Cancer Center stem cell program and the alpha clinic grant’s principal investigator. … Read the Full Story from the UC San Diego Health Newsroom

Novel Drug Targeting Leukemia Cells Enters Clinical Trial

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults. … Read the full story from the UC San Diego Newsroom


A team led by Dr. Thomas Kipps developed the new antibody, known as cirmtuzumab or UC-961. The work was conducted and supported by a California Institute for Regenerative Medicine HALT grant to co-principal investigators Dennis Carson, MD, and Catriona Jamieson, PhD, MD.

Dr. Thomas Kipps

Catriona H. M. Jamieson, MD, PhDDennis Carson, MD

L to R: Drs. Kipps, Jamieson and Carson.

Dr. Catriona Jamieson Announced as Inaugural Chief of New Division of Regenerative Medicine

Announced today by Wolfgang H. Dillmann, MD, Helen M. Ranney Distinguished Professor and Chair of the Department of Medicine

Catriona H. M. Jamieson, MD, PhD

Catriona Jamieson, MD, PhD

Please join me in officially welcoming Catriona Jamieson, MD, PhD, as the inaugural chief of the new Division of Regenerative Medicine. The Department of Medicine is delighted to announce the inception of the Division of Regenerative Medicine and we enthusiastically support Dr. Jamieson’s talent and vision for this innovative endeavor.

Wolfgang H. Dillmann, MD

Wolfgang H. Dillmann, MD

Dr. Jamieson joined the UC San Diego faculty in 2005 and is an associate professor of Medicine in the Division of Hematology-Oncology. She has proven her leadership skills, expertise and effectiveness in her current positions as director of the Stem Cell Research Program at Moores Cancer Center, co-leader of the Hematologic Malignancies Program, hematology team leader, co-director of the UC San Diego Stem Cell Training Grant, coordinating course director of the Interdisciplinary Stem Cell course, and a co-director of the new Sanford Stem Cell Clinical Center.

Dr. Jamieson received her medical and doctorate degrees from the University of British Columbia. She completed her residency and clinical fellowships in bone marrow transplantation and hematology, as well as her postdoctoral research fellowship in the laboratory of Professor Irving Weissman at Stanford.

As a physician-scientist, Dr. Jamieson specializes in leukemia and myeloproliferative neoplasms, which are a family of uncommon, but not rare, degenerative disorders in which the body overproduces blood cells. These disorders can cause blood clotting which can lead to heart attack, stroke, and other life-threatening complications including transformation to acute leukemia. Dr. Jamieson’s research focuses on the mutant stem cells and progenitor cells in myeloproliferative neoplasms, which can give rise to cancer stem cells. Her stem-cell research studies have taken a substantial leap from identifying a promising treatment in the laboratory to completing the first clinical trial targeting cancer stem cells in humans. Her discoveries in myeloproliferative neoplasms are now being brought together with a drug development track of a regional pharmaceutical company.

Please join me in giving your enthusiastic support to Dr. Jamieson in her new leadership role as the inaugural chief of the Division of Regenerative Medicine here at UC San Diego. This is a unique and exciting opportunity to make UC San Diego a key hub for the rapid translation of stem cell discoveries to the clinic.

$100 Million Gift Launches Sanford Stem Cell Clinical Center

UC San Diego-based effort will speed discoveries to new drugs and treatments for patients

Dr. Catriona Jamieson

In a bold and singular step toward delivering the therapeutic promise of human stem cells, businessman and philanthropist T. Denny Sanford has committed $100 million to the creation of the Sanford Stem Cell Clinical Center at the University of California, San Diego… Read the full story from the UC San Diego News Center

Pictured: Catriona H. M. Jamieson, MD, PhD, associate professor of medicine in the Division of Hematology-Oncology and director of stem cell research at the UC San Diego Moores Cancer Center.

Drug Targets Hard-to-Reach Leukemia Stem Cells Responsible for Relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive – and thus vulnerable – to a novel cancer stem cell-targeting drug currently under development. … Read the full story from the UCSD Newsroom


Catriona H. M. Jamieson, MD, PhDPrincipal investigator of the study is Catriona H. M. Jamieson, MD, PhD, associate professor of medicine in the Division of Hematology-Oncology and director of stem cell research at the UC San Diego Moores Cancer Center.

Dr. Jamieson is on the steering committee for the Moores Cancer Center’s My Answer to Cancer initiative for personalized cancer therapy. She is a member of the faculty in the UCSD Biomedical Sciences Graduate Program.

Citation for the report: Goff DJ, Recart AC, Sadarangani A, Chun H-J, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao K-H, Shazand K, Wentworth P, Smith KM, Jamieson CAM, Morris SR, Messer K, S.B. Goldstein LSB, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, and Jamieson CHM. (2013) A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition. Cell Stem Cell 10.1016/j.stem.2012.12.011, online January 17, 2013.

More about Dr. Jamieson and her work:

Enzyme Accelerates Malignant Stem Cell Cloning in Chronic Myeloid Leukemia

An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is increasing in prevalence. … Read the full story from the UCSD Newsroom


Catriona H. M. Jamieson, MD, PhDPrincipal investigator of the study is Catriona H. M. Jamieson, MD, PhD, associate professor of medicine in the Division of Hematology-Oncology and director of stem cell research at the UC San Diego Moores Cancer Center.

Dr. Jamieson is on the steering committee for the Moores Cancer Center’s My Answer to Cancer initiative for personalized cancer therapy. She is a member of the faculty in the UCSD Biomedical Sciences Graduate Program.

Department of Medicine faculty coauthor Sheldon R. Morris, MD, MPH, an investigator at the UCSD Antiviral Research Center,is health sciences assistant clinical professor in the Division of Infectious Diseases.

Citation for the report in PNAS: Jiang Q, Crews LA, Barrett CL, Chun H-J, Court AC, Isquith JM, Zipeto MA, Goff DJ, Minden M, Sadarangani A, Rusert JM, Dao K-HT, Morris SR, Goldstein LSB, Marra MA, Kelly A. Frazer KA, Jamieson C.H.M. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. PNAS 2012; published ahead of print December 28, 2012, doi:10.1073/pnas.1213021110

Read the study report (free full text)

More about Dr. Jamieson and her work: